David Esposito

David Esposito

Company: ONL Therapeutics

Job title: President & Chief Executive Officer


Demonstrating How Novel Imaging & Biomarker Technologies Enhance Early Clinical Interpretation 1:00 pm

Sharing clinical data from trials for Dry AMD, retinal detachment and glaucoma Assessing the practical application of imaging technologies, such as AST and DARC, in clinical development Determining the regulatory pathway to support broader application of novel imaging technologiesRead more

day: Conference Day Two

Roundtable Discussion 3:10 pm

Understanding the Relationship between the various retinal imaging biomarkers with disease progression Challenges associated with the interpretation of imaging data – do they demonstrate drug safety and efficacy? How can AI be used to further refine knowledge from retinal imaging? Discussing the role of AI in drug target identification, safety and efficacy assessment Moderator Feedback…Read more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.